EMA
https://www.bbc.co.uk/news/world-europe-56665150
possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within two weeks of vaccination
86 European cases
plausible explanation for these rare side effects is an immune response to the vaccine
18 deaths
Benefits of the vaccine outweighed the risk
25 million doses
(One case per 290,697 doses)
(One death per 1,388,888)
Could not list specific risk factors such as age or gender, but most blood clot cases were women under 60
Emer Cooke
No available evidence of specific risk factors such as age, gender, or previous medical history of clotting disorders
This vaccine has proven to be highly effective - it prevents severe disease and hospitalisation, and it is saving lives.
Belgium
Restrict AstraZeneca to those aged 56 and above
Italy
Over 60s
No evidence to stop people having a second dose of AstraZeneca
Spain
Restricting AstraZeneca to those between 60 and 64
France
Given only to those aged 0ver 55
Germany
Over 60s, plus high-priority groups
Under-60s who have received an AstraZeneca first dose should get a different vaccine for their second
Norway and Denmark
Full suspension
Germany also says its
World Health Organization's advisory vaccine safety panel
Blood clot link was plausible
not confirmed
very rare among 200 million people vaccinated with AstraZeneca globally
Statement from the Joint Committee on Vaccination and Immunisation (JCVI) on the use of the AstraZeneca COVID-19 vaccine
https://www.gov.uk/government/publications/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement
Acting on a precautionary basis, if these persons (under 30) are still unvaccinated, it is preferable for them to be offered an alternative COVID-19 vaccine, if available.
MHRA issues new advice, concluding a possible link between COVID-19 Vaccine AstraZeneca and extremely rare, unlikely to occur blood clots
https://www.gov.uk/government/news/mhra-issues-new-adv..
